Oncoresponse Inc., of Houston, said it raised $7 million in a supplemental series A financing, consisting of a $3.5 million investment from Greatpoint Ventures and $3.5 million from the Helsinn Investment Fund. In October 2015, the company secured $9.5 million as part of an initial closing of its series A financing; an additional $3 million investment by Baxalta, acquired by Shire plc in May, along with the current investments bring the total series A financing to $19.5 million, which will be used to support its ongoing efforts to interrogate the humoral response of elite responders to cancer immunotherapy to identify antibodies and potential targets for therapeutic development.